
GH Research gets FDA clearance to start phase 3 trial for new depression treatment in 2026
GH Research PLC has resolved the FDA clinical hold on its investigational new drug (IND) application for GH001, a treatment targeting resistant depression. This clearance allows the company to plan a pivotal phase 3 trial expected to begin in 2026. G...





